ClinicalTrials.gov
ClinicalTrials.gov Menu

A Clinical Study to Investigate the Effect of a Partially Hydrolysed Infant Formula With Added Synbiotics on Gut Microbiota Composition and Clinical Effectiveness in Infants at High Risk of Developing Allergy (TEMPO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03067714
Recruitment Status : Recruiting
First Posted : March 1, 2017
Last Update Posted : August 22, 2017
Sponsor:
Information provided by (Responsible Party):
Nutricia Research

Brief Summary:
With the rising prevalence of allergic diseases and the subsequent risk of developing other immune-related disorders, primary prevention of allergy has become a major priority. It is generally acknowledged that breastfeeding is one of the main pillars in allergy prevention. Infant formulas based on hydrolysed proteins have been developed to be used by infants at increased risk of developing allergy in case a mother is unable or chooses not to breastfeed her infant. It has recently been demonstrated that the gut microbiota composition and microbiota activity of infants receiving an infant formula based on partially hydrolysed proteins, supplemented with oligosaccharides, is more similar to breastfed infants than to infants receiving standard cow's milk formula, demonstrated by increased levels of bifidobacteria. However the interaction between microbial changes impacted by an hypoallergenic concept and its influence on early life immune development should be further explored. The aim of the present study is therefore to investigate the bifidogenic effect of a hypoallergenic formula supplemented with prebiotics and probiotics compared to standard infant formula in infants at increased risk of developing allergic disease. This study will secondary assess the effects of this concept on the development of allergic manifestations up to the age of 12 months, which will be verified in a separate clinical study MAESTRO as primary outcome. Furthermore, the effects on growth and safety will be studied.

Condition or disease Intervention/treatment Phase
Immunity Other: Infant formula with added synbiotics Other: Standard infant formula Phase 3

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 700 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: A Randomised, Double-blind, Controlled, Parallel-group, Multi-country Study to Investigate the Effect of a Partially Hydrolysed Infant Formula With Added Synbiotics on Gut Microbiota Composition and Clinical Effectiveness in Infants at High Risk of Developing Allergy
Actual Study Start Date : March 30, 2017
Estimated Primary Completion Date : March 2019
Estimated Study Completion Date : March 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Active product: partially hydrolysed formula + synbiotics Other: Infant formula with added synbiotics
Intervention group: Infant Formula / Follow-On formula with partially hydrolysed cow's milk protein supplemented with prebiotics and probiotics.

Active Comparator: Control product: standard formula (intact protein) Other: Standard infant formula
Control group: Standard Infant Formula / Follow-On formula with intact cow's milk protein (only standard ingredients, without addition of pre- and probiotics).




Primary Outcome Measures :
  1. Faecel levels of Bifidobacteria [ Time Frame: 17 weeks ]
    Levels of Bifidobacteria at 17 weeks of age - stool sample


Secondary Outcome Measures :
  1. Faecal levels of Bifidobacteria and adult-like bacterial cluster [ Time Frame: 52 weeks ]
    Levels of Bifidobacteria and adult-like bacterial cluster up to 52 weeks of age - stool sample

  2. IgE-mediated allergic manifestations [ Time Frame: 52 weeks ]
    IgE-mediated allergic manifestations up to 52 weeks of age - blood sample



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   up to 16 Weeks   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Healthy term infants (gestational age ≥ 37 and ≤ 42 weeks) at high risk of developing allergy based on family history of allergy (*1).
  2. Infants aged ≤ 16 weeks (max. 16 weeks + 0 days), preferably as soon as possible after birth.
  3. Infants with birth weight within normal range for gestational age and sex (10th to 90th percentile according to local applicable growth charts).
  4. Infants who start formula feeding within 16 weeks of age (infants of mothers who have chosen not to breastfeed or mothers who completely/partially cease breastfeeding before the subject's age of 16 weeks) OR Infants who are exclusively breastfed and whose mothers have the intention to exclusively breastfeed at least until their infant is 16 weeks of age (*2).
  5. Written informed consent from one or both parents (according to local laws) and/or legal guardian.

    • 1)Family history of allergy is defined as at least one first-degree relative (parent or full sibling) with: 1) self-reported historically doctor confirmed allergic disease (allergic rhinitis, asthma, food allergy, allergic eczema); or 2) self-reported historically non-doctor confirmed allergic disease (allergic rhinitis, asthma, food allergy, allergic eczema) in combination with positive skin prick test.
    • 2)Subjects whose mother intents to switch to formula feeding before the subject's age of 16 weeks but in the end still exclusively breastfeed, will be included in the breastfed reference group. The other way around, subjects whose mother intents to exclusively breastfeed for at least 16 weeks, but in the end decides to switch to formula earlier, will be included in the randomised groups. All these subject s should meet all other in-/exclusion criteria.

Exclusion Criteria:

  1. Consumption of any amount of infant formula based on intact protein before randomisation.
  2. Consumption of any amount of infant formula with added probiotics and/or probiotic supplement before randomisation.
  3. Existing allergic manifestations (e.g. allergic skin disorders, food allergy) before randomisation according to investigator's clinical assessment.
  4. Severe congenital abnormalities which could influence the subjects' growth (e.g. cystic fibrosis, bronchopulmonary dysplasia, tracheomalacia, tracheoesophageal fistula, major congenital heart disease, or any other condition according to investigator's clinical judgement).
  5. Severe neonatal illnesses (e.g. respiratory distress syndrome, severe sepsis intraventricular hemorrhage, severe neonatal jaundice, necrotizing enterocolitis, persistent pulmonary hypertension of the newborn, or any other condition which required the use of intravenous antibiotic).
  6. Known underlying disease predisposing to infection (e.g. HIV, viral hepatitis B, and C, auto-immune diabetes, immune deficiency).
  7. Severe renal failure and hepatic failure according to investigator's clinical judgement.
  8. Incapability of the parents to comply with study protocol or investigator's uncertainty about the willingness or ability of the subject to comply with the protocol requirements
  9. Participation in other studies involving investigational or marketed products concomitantly or within two weeks prior to screening visit.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03067714


Contacts
Contact: Jan van der Mooren +31 30 209 5000 jan.vandermooren@danone.com

Locations
Belgium
Algemeen Stedelijk Ziekenhuis Active, not recruiting
Aalst, Belgium
Cliniques universitaires Saint-Luc Active, not recruiting
Brussels, Belgium
Czechia
Prakticky lekar pro deti a dorost Recruiting
Praha, Czechia
Principal Investigator: R. Ruzkova         
Nemocnice Strakonice, a.s. Recruiting
Strakonice, Czechia
Principal Investigator: M. Gregora         
Netherlands
Amphia Ziekenhuis Recruiting
Breda, Brabant, Netherlands, 4819 EV
Principal Investigator: R.H.T van Beek         
VU University Medical Center Active, not recruiting
Amsterdam, Netherlands
Deventer Ziekenhuis Active, not recruiting
Deventer, Netherlands
Slovakia
PEGYS s.r.o. Recruiting
Dolný Kubín, Slovakia
Principal Investigator: M. Ondrejkova         
Juvenalia, s.r.o. Active, not recruiting
Dunajská Streda, Slovakia
PEDMAN s.r.o. Recruiting
Martin, Slovakia
Principal Investigator: D. Mankova         
Sponsors and Collaborators
Nutricia Research

Responsible Party: Nutricia Research
ClinicalTrials.gov Identifier: NCT03067714     History of Changes
Other Study ID Numbers: EBB15BL89847
First Posted: March 1, 2017    Key Record Dates
Last Update Posted: August 22, 2017
Last Verified: August 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No